|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 5. Effect of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists on the Risk of Incident Gastric Cancer (cDDD ≥180 days) a** | | | | | | | | | |
|  | | No. of subjects | Person-years | No. of gastric cancer cases | Incidence rate/1000 person-years (95% CI) | Crude hazard ratio (95% CI) | *P* | Adjusted hazard ratio (95% CI)b | *P* |
| Full unweighted cohort c | |  |  |  |  |  |  |  |  |
|  | PPI | 66797 | 282003 | 742 | 2.63 (2.45, 2.83) | 1.20 (1.07, 1.33) | 0.0012 | 1.01 (0.90, 1.14) | 0.854 |
|  | H2RA | 55321 | 288213 | 618 | 2.14 (1.98, 2.32) | 1.00 (reference) |  | 1.00 (reference) |  |
| Propensity-score -weighted cohort d | |  |  |  |  |  |  |  |  |
|  | PPI | 39799 | 182643 | 411 | 2.25 (2.04, 2.48) | 1.01 (0.88, 1.16) | 0.8901 | 1.01 (0.88, 1.16) | 0.846 |
|  | H2RA | 38967 | 178846 | 397 | 2.22 (2.01, 2.45) | 1.00 (reference) |  | 1.00 (reference) |  |
| Propensity score–matched cohort e | |  |  |  |  |  |  |  |  |
|  | PPI | 38512 | 176313 | 421 | 2.39 (2.17, 2.63) | 1.04 (0.91, 1.19) | 0.5908 | 1.05 (0.91, 1.20) | 0.519 |
|  | H2RA | 38512 | 172584 | 396 | 2.29 (2.08, 2.53) | 1.00 (reference) |  | 1.00 (reference) |  |
| cDDD, cumulative defined daily dose; H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor; CI, confidence interval  a PPI long-term use was defined as only PPI use, PPI ≥ 180 cDDD-days, and combined use, PPI ≥ 180 cDDD-days and H2RA < 180 cDDD-days or PPI ≥ 180 cDDD-days and H2RA ≥ 180 cDDD-days. H2RA long-term use was defined as only H2RA use, H2RA ≥ 180 cDDD-days, and combined use of H2RA ≥ 180 cDDD-days and PPI < 180 cDDD-days.  b Adjusted for age, sex, calendar period of prescription, time from medication start to 180 cDDD-days (month), socioeconomic characteristics (income, smoking, and alcohol use), indication for drug use (GERD or peptic ulcer), Charlson Comorbidity Index, *H. pylori* eradication, and use of other medications (aspirin, metformin, and statin). c Unadjusted and adjusted subdistribution hazards were obtained from the Fine and Gray model between PPI long-term users and H2RA long-term users from the unweighted cohort, which accounted for competing risks.  d Unadjusted and adjusted subdistribution hazards were obtained from the Fine and Gray model between PPI long-term users and H2RA long-term users from the propensity-score weighted cohort, which accounted for competing risks.  e Unadjusted and adjusted subdistribution hazards were obtained from the Fine and Gray model between PPI long-term users and H2RA long-term users from the propensity score–matched cohort, which accounted for competing risks. | | | | | | | | | |